

***Toxoplasma gondii* Low-Level
Pyrimethamine-Resistance Plasmid
(pDHFR-TSc3/M3), Recombinant in
*Escherichia coli***

Catalog No. ARP-2853

This reagent is the tangible property of the U.S. Government.

Lot No. 95033

Manufacturing Date: Unknown; before 1998

For research use only. Not for human use.

Contributor:

David S. Roos, E. Otis Kendall Professor of Biology, Department of Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA and Bruce K. Brown, Project Director, National Institutes of Health AIDS Reagent Program, Germantown, Maryland, USA

Manufacturer:

David S. Roos, E. Otis Kendall Professor of Biology, Department of Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Product Description:

ARP-2853 is an *Escherichia coli* (*E. coli*) DH5 α stock containing a plasmid, pDHFR-RSc3/M3 (also referred to as pDHFR-RSc3/T83N¹), which confers low-level resistance to pyrimethamine.^{1,2} The *Toxoplasma gondii* dihydrofolate reductase-thymidylate synthase (*T. gondii dhfr-ts*) minigene, with the 5' genomic flanking sequence fused to cDNA, was cloned into the pKS- polylinker *HindIII-EcoRI* sites. An additional *EcoRI* site occurs near the *dhfr-ts* junction. The vector *BamHI* site has been filled. The wild-type *dhfr-ts* coding sequence contains a Thr83(ACC)-Asn(AAC) mutation that confers low-level pyrimethamine resistance to transfected parasites. This mutation is analogous to Ser108-Asn in fansidar-resistant *Plasmodium falciparum*.^{1,2}

ARP-2853 is suitable for stable transformation of *T. gondii*. Transformants should be isolated at low frequency (-4), and will typically contain multiple chromosomal or episomal transgenes, with a copy number roughly proportional to selection pressure. Linked genes may be co-amplified along with the selectable marker.²

Note: This plasmid confers resistance to pyrimethamine in *T. gondii*, rendering traditional pyrimethamine/sulfa therapy ineffective. In the event of accidental infection, alternative treatment (e.g., clindamycin and sulfa) should be administered immediately. Transgenic parasites harboring pyrimethamine resistance genes are not to be introduced into animals.

Material Provided:

Each vial contains approximately 500 μ L of *E. coli* DH5 α with pDHFR-TSc3/M3 plasmid in Luria Bertani (LB) broth supplemented with 10% glycerol.

Packaging/Storage:

ARP-2853 was packaged aseptically in plastic cryovials. The product is provided frozen on dry ice and should be stored at -60°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Growth Conditions:

Media:

LB broth or agar

pDHFR-TSc3/M3 contains the gene required for pyrimethamine resistance. The standard concentration of pyrimethamine in culture is 150 ng per mL.

Incubation:

Temperature: 37°C

Atmosphere: Aerobic

Propagation:

Incubate the tube, slant and/or plate at 37°C for 1 day.

Citation:

Acknowledgment for publications should read "The following reagent was provided by the NIH AIDS Reagent Program for distribution by BEI Resources, NIAID, NIH: *Toxoplasma gondii* Low-Level Pyrimethamine-Resistance Plasmid (pDHFR-TSc3/M3), Recombinant in *Escherichia coli*, ARP-2853, contributed by Dr. David S. Roos."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Roos, D. S., et al. "Molecular Tools for the Genetic Dissection of the Protozoan Parasite *Toxoplasma gondii*." Methods Cell Biol. 45 (1994): 27-63. PubMed: 7707991.
2. Donald, R. G. and D. S. Roos. "Stable Molecular Transformation of *Toxoplasma gondii*: A Selectable Dihydrofolate Reductase-Thymidylate Synthase Marker Based on Drug-Resistance Mutations in Malaria." Proc. Natl. Acad. Sci. USA 90 (1993): 11703-11707. PubMed: 8265612.

ATCC® is a trademark of the American Type Culture Collection.

